IL6 and depressive disorder: Based on the evidence reviewed here, it is predicted that increasing n-3 fatty acid status of MDD patients to ≥8% would be associated with a significant reduction in CHD risk factors, including depression symptom severity, nonfasting triglyceride levels, indices of platelet aggregation, CRP and IL-6 levels, and ultimately reduced risk for emergent cardiac events and SCD.